Please login to the form below

Not currently logged in
Email:
Password:

European Commission approves Firazyr

German pharmaceutical company, Jerini, has been granted marketing approval by the European Commission for their hereditary angioedema drug, Firazyr
German pharmaceutical company, Jerini, has been granted marketing approval by the European Commission for their hereditary angioedema (HAE) drug, Firazyr.

The approval allows Jerini to market Firazyr in all 27 EU countries ñ the first HAE drug to receive EU-wide approval.

HAE is a debilitating and potentially life-threatening genetic disease causing unpredictable, recurring swelling attacks. While swellings in the hands, feet and face can be disfiguring, swellings in the larynx constrict the airways and can be life-threatening.

Firazyr works by blocking the B2 receptor as an antagonist to a hormone that has been shown to be elevated in HAE patients. Firazyr has been granted orphan drug status for the treatment of angioedema by the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA).

Earlier this month, Jerini entered into a partnership, which included a voluntary public takeover bid, with Shire Ltd. The deal is expected to be complete by the end of Q3 2008.

Sylvie Gregoire, president of Shire Human Genetic Therapies (HGT) business said: "We are very pleased that European approval has been granted to Jerini today. This is an important step in bringing this first-in-class orphan treatment to patients who suffer from HAE attacks. We look forward to the completion of our transaction with Jerini which will enable us to work together and ultimately build Firazyr into a global gold standard treatment."

15th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics